Ultra-slow, low-dose infusions of thrombolysis may offer a safe and effective alternative to further interventions in the management of transcatheter aortic valve replacement (TAVR) thrombosis, particularly for patients who are resistant to standard therapies or clinically unstable, a new review suggests.